Therapies Approaches in Venous Thromboembolism Management and Coagulation

Venous thromboembolism (VTE) remains a critical public health concern due to its high prevalence, significant morbidity, mortality, and economic impact. In the U.S. alone, approximately 900,000 cases are estimated annually with a mortality rate as high as 30% within the first month after diagnosis. Although current treatments like Vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) are effective, they come with heightened bleeding risks. Hence, there is an unmet need for safer therapeutic alternatives that effectively manage and prevent VTE without increasing bleeding tendencies.

This Research Topic aims to delve deeper into the different therapeutic approach for VTE. The use of Direct Oral Anticoagulant versus Vitamin K antagonists, the different extention of therapy or the association with others drugs that patients took for others clinical indications (such as statins for dyslipidemia) is common for managing of provoked and unprovoked venous thromboembolism (VTE), but real-world data on dosing decisions and their association with outcomes are limited.

To gain further insights into how different therapeutic approaches can revolutionize the management of VTE, we welcome articles that address, but are not limited to, the following topics:

• Original Research on the management of therapy for VTE

• Case reports and series delineating the management of therapy for VTE

• Comprehensive reviews discussing the management of therapy for VTE

With this focused compilation, we aim to enhance current understanding and explore innovative therapeutic possibilities within the realm of VTE treatment, potentially guiding future clinical practices.